Logo Image
In Brief

AstraZeneca completes Icosavax acquisition for $1.1bn

AstraZeneca will bolster its vaccine pipeline with a Phase III-ready candidate for respiratory infections.

Latest news

Pfizer’s VELSIPITY receives EC approval for ulcerative colitis

The approval is based on findings from the ELEVATE UC Phase III programme, comprising the ELEVATE UC 52 and ELEVATE UC 12 trials.

Daiichi Sankyo and AstraZeneca’s lung cancer antibody set for FDA review

An FDA approval in late 2024 would make it the first TROP2-directed therapy for non-small cell lung cancer (NSCLC) antibody drug conjugate patients.

US FDA accepts review of argenx’s VYVGART Hytrulo for CIDP

The supplemental biologics licence application (sBLA) submission is based on findings from the ADHERE study, which assessed VYVGART Hytrulo in adults.

Applied aims for approval post-Phase III win with SORD deficiency drug 

Applied plans to submit a new drug application following the announcement of positive interim data from its Phase III trial.

Gilead signs antibody deal with Biocytogen amid ADC buzz

Biocytogen and Gilead are entering an antibody deal to leverage the discovery and development of new antibody therapeutics.

Almirall licenses IL-21 antibody from Novo Nordisk

Novo Nordisk will receive upfront, milestone and royalty payments for developing and marketing the dermatology asset.

Singapore HSA accepts AffaMed’s NDA for ocular treatment

DEXTENZA offers dexamethasone to the ocular surface for up to 30 days without the use of preservatives.